Antibody Responses to SARS-CoV-2 Antigens in Humans and Animals.
COVID-19
SARS-CoV-2
antibody
respiratory viruses
vaccine
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
16 Nov 2020
16 Nov 2020
Historique:
received:
28
10
2020
revised:
10
11
2020
accepted:
12
11
2020
entrez:
19
11
2020
pubmed:
20
11
2020
medline:
20
11
2020
Statut:
epublish
Résumé
To optimize the public health response to coronavirus disease 2019 (COVID-19), we must first understand the antibody response to individual proteins on the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) and the antibody's cross reactivity to other coronaviruses. Using a panel of 37 convalescent COVID-19 human serum samples, we showed that the magnitude and specificity of responses varied across individuals, independent of their reactivity to seasonal human coronaviruses (HCoVs). These data suggest that COVID-19 vaccines will elicit primary humoral immune responses in naïve individuals and variable responses in those previously exposed to SARS-CoV-2. Unlike the limited cross-coronavirus reactivities in humans, serum samples from 96 dogs and 10 cats showed SARS-CoV-2 protein-specific responses focused on non-S1 proteins. The correlation of this response with those to other coronaviruses suggests that the antibodies are cross-reactive and generated to endemic viruses within these hosts, which must be considered in seroepidemiologic studies. We conclude that substantial variation in antibody generation against coronavirus proteins will influence interpretations of serologic data in the clinical and veterinary settings.
Identifiants
pubmed: 33207583
pii: vaccines8040684
doi: 10.3390/vaccines8040684
pmc: PMC7712576
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : HHSN272201400006C
Pays : United States
Références
Nature. 2020 Oct;586(7831):776-778
pubmed: 32408337
Nature. 2020 Aug;584(7821):353-363
pubmed: 32659783
PLoS Pathog. 2019 Dec 19;15(12):e1008109
pubmed: 31856206
Science. 2020 Aug 7;369(6504):731-736
pubmed: 32540900
Cell Rep. 2020 Jun 2;31(9):107725
pubmed: 32426212
Epidemiol Infect. 1990 Oct;105(2):435-46
pubmed: 2170159
J Virol. 1990 Mar;64(3):1407-9
pubmed: 2154621
Nat Commun. 2020 Dec 4;11(1):6231
pubmed: 33277505
Lancet. 2020 Jun 13;395(10240):1845-1854
pubmed: 32450106
Nature. 2020 Oct;586(7830):583-588
pubmed: 32731257
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033173
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033172
Proc Natl Acad Sci U S A. 2020 Sep 8;117(36):22311-22322
pubmed: 32826334
J Virol. 2020 Feb 14;94(5):
pubmed: 31826992
J Infect. 2020 Sep;81(3):e68-e69
pubmed: 32579982
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
Proc Natl Acad Sci U S A. 2020 Oct 6;117(40):24790-24793
pubmed: 32948692
Sci Immunol. 2020 Jun 11;5(48):
pubmed: 32527802
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Nat Med. 2020 Nov;26(11):1691-1693
pubmed: 32929268
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9
pubmed: 15210961
Virol J. 2014 May 06;11:82
pubmed: 24885320
J Virol. 2004 Apr;78(7):3572-7
pubmed: 15016880
Lancet Infect Dis. 2020 Oct 12;:
pubmed: 33058797
J Korean Med Sci. 2020 Aug 24;35(33):e311
pubmed: 32830472
Emerg Infect Dis. 2009 Sep;15(9):1445-52
pubmed: 19788813